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Despite periods of feeding and fasting, plasmaglucose remains in a narrow range between 4and 7 mM in normal individuals. This tightcontrol is governed by the balance betweenglucose absorption from the intestine,
production by the liver and uptake and metabolism by
peripheral tissues. Insulin increases glucose uptake in
muscle and fat (see Box 1), and inhibits hepatic glucose
production, thus serving as the primary regulator of blood
glucose concentration. Insulin also stimulates cell growth
and differentiation, and promotes the storage of substrates
in fat, liver and muscle by stimulating lipogenesis,
glycogen and protein synthesis, and inhibiting lipolysis,
glycogenolysis and protein breakdown (Fig. 1). Insulin
resistance or deficiency results in profound dysregulation
of these processes, and produces elevations in fasting and
postprandial glucose and lipid levels.
Insulin increases glucose uptake in cells by stimulating
the translocation of the glucose transporter GLUT4 from
intracellular sites to the cell surface (see Box 1). Up to 75% of
insulin-dependent glucose disposal occurs in skeletal 
muscle, whereas adipose tissue accounts for only a small
fraction1. Despite this, mice with a knockout of the insulin
receptor in muscle have normal glucose tolerance2, whereas
those with a knockout of the insulin-sensitive glucose 
transporter in fat have impaired glucose tolerance, 
apparently owing to insulin resistance being induced in
muscle and liver3. Both obesity and lipoatrophy also cause
insulin resistance and predisposition to type 2 diabetes,
demonstrating that adipose tissue is crucial in regulating
metabolism beyond its ability to take up glucose4. Although
insulin does not stimulate glucose uptake in liver, it blocks
glycogenolysis and gluconeogenesis, and stimulates 
glycogen synthesis, thus regulating fasting glucose levels.
Insulin action in tissues not normally considered insulin
sensitive, including brain and pancreatic b-cell, may also be 
important in glucose homeostasis2,5 (see below). 
Proximal insulin-signalling pathways
The insulin receptor 
The insulin receptor belongs to a subfamily of receptor tyro-
sine kinases that includes the insulin-like growth factor
(IGF)-I receptor and the insulin receptor-related receptor
(IRR)6. These receptors are tetrameric proteins consisting of
two a- and two b-subunits that function as allosteric
enzymes in which the a-subunit inhibits the tyrosine kinase
activity of the b-subunit. Insulin binding to the a-subunit
leads to derepression of the kinase activity in the b-subunit
followed by transphosphorylation of the b-subunits and a
conformational change that further increases kinase 
activity6. Insulin, IGF-I and the IRR receptors can form
functional hybrids; thus, an inhibitory mutation in one
receptor can inhibit the activity of the others7. 
Homologues of the insulin/IGF-I receptor have been
identified in Drosophila, Caenorhabditis elegans and meta-
zoan marine sponges8. These lower organisms use some of
the same downstream signals critical to the regulation of
mammalian cells, including phosphatidylinositol-3-OH
kinase (PI(3)K), Akt and forkhead transcription factors.
Inhibitory mutants of the insulin/IGF system in C. elegans
live longer than normal animals, raising a number of 
interesting questions about the association of hyperinsuli-
naemia/insulin resistance with conditions that shorten 
life span, such as obesity, diabetes and accelerated 
atherosclerosis.
Insulin-receptor substrates
At least nine intracellular substrates of the insulin/IGF-I
receptor kinases have been identified (Fig. 2). Four of these
belong to the family of insulin-receptor substrate (IRS) 
proteins9. Other substrates include Gab-1, p60dok, Cbl, APS
and isoforms of Shc10. The phosphorylated tyrosines in
these substrates act as ‘docking sites’ for proteins that con-
tain SH2 (Src-homology-2) domains. Many of these SH2
proteins are adaptor molecules, such as the p85 regulatory
subunit of PI(3)K and Grb2, or CrkII, which activate small G
proteins by binding to nucleotide exchange factors. Others
are themselves enzymes, including the phosphotyrosine
phosphatase SHP2 and the cytoplasmic tyrosine kinase Fyn.
Substrate binding to these SH2 proteins can regulate their
activities, or in some cases their subcellular location.
Although the IRS proteins are highly homologous,
recent studies in knockout mice and cell lines suggest that
they serve complementary, rather than redundant, roles in
insulin/IGF-I signalling. IRS-1-knockout mice exhibit gen-
eralized pre- and post-natal growth retardation, as well as
insulin resistance in peripheral tissues and impaired glucose
tolerance11,12. IRS-2-knockout mice also exhibit insulin
Insulin signalling and the regulation of 
glucose and lipid metabolism
Alan R. Saltiel* & C. Ronald Kahn†
*Life Sciences Institute, Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA 
(e-mail: saltiel@umich.edu)
†Joslin Diabetes Centre, Harvard Medical School, Boston, Massachusetts 02215, USA (e-mail: c.ronald.kahn@joslin.harvard.edu)
The epidemic of type 2 diabetes and impaired glucose tolerance is one of the main causes of morbidity and
mortality worldwide. In both disorders, tissues such as muscle, fat and liver become less responsive or
resistant to insulin. This state is also linked to other common health problems, such as obesity, polycystic
ovarian disease, hyperlipidaemia, hypertension and atherosclerosis. The pathophysiology of insulin resistance
involves a complex network of signalling pathways, activated by the insulin receptor, which regulates
intermediary metabolism and its organization in cells. But recent studies have shown that numerous other
hormones and signalling events attenuate insulin action, and are important in type 2 diabetes.
© 2001 Macmillan Magazines Ltd
resistance in both peripheral tissues and liver, but have defective
growth in only some tissues, including certain regions of the brain,
islets and retina13,14. In the IRS-2–/– mouse, this multifactorial insulin
resistance combined with decreased b-cell mass leads to develop-
ment of type 2 diabetes14. By contrast, IRS-3- and IRS-4-knockout
mice have normal or near normal growth and metabolism15.
The different IRS proteins seem to serve different functions at the
cellular level, probably owing to differences in tissue distribution,
subcellular localization and intrinsic activity of the proteins. 
IRS-1-knockout cells exhibit reduced IGF-I-stimulated DNA 
synthesis11,12 and fail to differentiate into adipocytes in culture16.
Likewise, the mitogenic response mediated by IRS-2 is weaker than
that by produced by IRS-1 (ref. 17). IRS-2-knockout cells show a
major defect in insulin-stimulated glucose transport14. The roles 
of IRS-3 and 4 are less clear in cultured cells, but some data 
suggest that these substrates may act as negative regulators of IRS-1
and -2 (ref. 18). 
Inhibition of insulin-receptor signalling
In addition to tyrosine phosphorylation, both the insulin receptor
and IRS proteins undergo serine phosphorylation, which may 
attenuate signalling by decreasing insulin-stimulated tyrosine 
phosphorylation19 and promote interaction with 14-3-3 proteins20.
These inhibitory phosphorylations provide negative feedback to
insulin signalling and serve as a mechanism for cross-talk from other
pathways that produce insulin resistance. Several kinases have been
implicated in this process, including PI(3)K, Akt, glycogen synthase
kinase (GSK)-3 and mammalian target of rapamycin (mTOR).
Recent data indicate that obesity-induced attenuation of insulin 
signalling might arise from the sequential activation of protein
kinase C (PKC) and inhibitor of nuclear factor-kB (IkB) kinase,
although the details of this pathway have not been elucidated21,22. 
Insulin action is also attenuated by protein tyrosine phosphatases
(PTPases), which catalyse the rapid dephosphorylation of the 
receptor and its substrates. A number of PTPases have been identified
that catalyse dephosphorylation of the insulin receptor in vitro, some
of which are expressed in insulin-responsive cells, or upregulated in
states of insulin resistance. Most attention has focused on the 
cytoplasmic phosphatase PTP1B. Knockout of PTP1B leads to
increased tyrosine phosphorylation of the insulin receptor and IRS
proteins in muscle and improved insulin sensitivity23. PTP1B–/– mice
are also resistant to diet-induced obesity, suggesting the brain as an
important site of action. This combination of effects implicates
PTP1B as a potential therapeutic target in diabetes and obesity.
PI(3)K and insulin action
PI(3)K has a pivotal role in the metabolic and mitogenic actions of
insulin and IGF-I (ref. 24). Inhibitors of class Ia PI(3)K, or transfec-
tions with dominant negative constructs of the enzyme, block 
most metabolic actions of insulin, including stimulation of glucose
transport, glycogen and lipid synthesis. PI(3)K consists of a p110
catalytic subunit and a p85 regulatory subunit that possesses two
SH2 domains that interact with tyrosine-phosphorylated 
pYMXM and pYXXM motifs in IRS proteins25. At least eight 
isoforms of the regulatory subunits have been identified. These 
are derived from three genes (p85a, p85b and P55PIK)26 and 
alternative splicing of p85a to produce AS53/p55a27 and p50a28. Of
these, p85a is predominant and thought to be the main response
pathway for most stimuli. 
The exact roles of the different regulatory subunits of PI(3)K in
insulin action are unclear. Splice variants possess differences in
potencies for enzyme activation27, tissue distribution27,28 and 
sensitivity to insulin29. Knockout mice with a disruption of all three
isoforms derived from the p85a gene die shortly after birth30, whereas
heterozygous knockout mice or mice lacking only full-length p85a
are viable and exhibit improved insulin sensitivity (ref. 31, and F.
Mauvais-Jarvis et al., personal communication). Cell lines derived
from heterozygous knockouts also exhibit increased insulin/IGF-I
signalling, which seem to be due to improved stoichiometry of the
interaction (see below).
The activation of PI(3)K may transmit multiple signals. PI(3)K
catalyses the phosphorylation of phosphoinositides on the 3-posi-
tion to produce phosphatidylinositol-3-phosphates, especially
PtdIns(3,4,5)P3, which bind to the pleckstrin homology (PH)
domains of a variety of signalling molecules thereby altering their
activity or subcellular localization32. Moreover, PI(3)K also possesses
serine kinase activity, and both the regulatory and catalytic subunits
of the enzyme can interact with other signalling proteins. Indeed,
recent studies suggest that these proteins may be important in insulin
action independent of PtdIns(3,4,5)P3 generation
33.
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Insulin increases glucose transport in fat and muscle cells by
stimulating the translocation of the transporter GLUT4 from
intracellular sites to the plasma membrane (see figure below).
GLUT4 is found in vesicles that continuously cycle from intracellular
stores to the plasma membrane. Insulin increases glucose transport
by increasing the rate of GLUT4-vesicle exocytosis, and by slightly
decreasing the rate of internalization99. Although the exact
mechanisms are unknown, it is likely that the insulin-responsive
GLUT4 vesicle is tethered to intracellular sites, perhaps defined by a
microtubule network100. Phosphorylation events probably catalysed
by PtdIns(3,4,5)P3-dependent kinases release vesicles from these
sites, allowing trafficking of GLUT4 to the cell surface. Recent
evidence suggests that these vesicles move along microtubule
tracks en route to the cell surface, perhaps via kinesin motors. The
vesicles then dock and fuse with the plasma membrane, allowing
the extracellular exposure of the GLUT4 protein.
It is likely that the actin cytoskeleton is also crucial in insulin-
stimulated GLUT4 translocation. Insulin causes remodelling of
cortical actin filaments just below the plasma membrane, and
induces membrane ruffling. This effect probably reflects actin
polymerization and depolymerization involving lamelipodia and/or
filopodia formation. The actin depolymerizing agent cytochalasin D,
as well as the actin monomer-binding toxins latrunculin A and B,
partially inhibit the effects of insulin on actin and GLUT4
translocation.
The docking and fusion of the GLUT4 vesicle at the plasma
membrane may also be subject to regulation by insulin. The 
v-SNARE protein VAMP2 physically
interacts with its t-SNARE counterpart
syntaxin 4 on GLUT4 vesicles during
vesicle docking and fusion with the
plasma membrane99. Although these
SNARE interactions are essential,
neither SNARE protein seems to be a
direct target of insulin. Instead, the
SNARE accessory proteins Synip and
Munc18c may be involved in the control




The regulation of glucose transport
Box 1 Figure 3T3L1 adipocytes were transfected with a fusion construct of GLUT4
and enhanced green fluorescent protein. Cells were treated with or without insulin.
The image is a confocal micrograph of single cells, showing the translocation of the
GLUT4 protein from intracellular sites to the cell surface. For a three-dimensional
image of these cells, visit http://www.medgen.med.umich.edu/labs/saltiel/.
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Phosphotidylinositol-3-phosphates regulate three main classes of
signalling molecules: the AGC family of serine/threonine protein
kinases34, guanine nucleotide-exchange proteins of the Rho family of
GTPases35, and the TEC family of tyrosine kinases36. PI(3)K also acti-
vates the mTOR/FRAP pathway, and might be involved in regulation
of phospholipase D, leading to hydrolysis of phosphatidylcholine and
increases in phosphatidic acid and diacylglycerol. The best character-
ized of the AGC kinases is phosphoinositide-dependent kinase 1
(PDK1), one of the serine kinases that phosphorylates and activates
the serine/threonine kinase Akt/PKB37. Akt possesses a PH domain
that also interacts directly with PtdIns(3,4,5)P3, promoting 
membrane targeting of the protein and catalytic activation. Akt has
been suggested to be important in transmission of the insulin signal,
by phosphorylation of the enzyme GSK-3 (see below), the forkhead
transcription factors and cAMP response element-binding 
protein38,39. Although studies using inhibitory or activated forms of
Akt have not uniformly inhibited or mimicked insulin actions40,
deletion of Akt2 produces hepatic insulin resistance in mice41. Other
AGC kinases that are downstream of PI(3)K include serum- and glu-
cocorticoid-regulated kinase and the atypical PKCs, PKC-z and -l42.
Akt and/or the atypical PKCs seem to be required for insulin-
stimulated glucose transport. 
Activity of this pathway is also determined by phosphatidylinosi-
tol-3-phosphates such as phosphatase and tensin homologue43 and
the SH2 domain-containing inositol-5-phosphatase SHIP2 (ref. 44).
Overexpression of these enzymes leads to decreased levels of
PtdIns(3,4,5)P3. This might terminate signal transduction and/or
change the nature of the phosphoinositides, altering the binding
specificity to PH or phox homology domains. Disruption of these
genes or reducing expression of these messenger RNAs yields mice
with increased insulin sensitivity45. 
The CAP/Cbl pathway and lipid rafts
In addition to PI(3)K activity, other signals seem to be required for
insulin-stimulated glucose uptake10. This second pathway appears to
involve tyrosine phosphorylation of the Cbl protooncogene46. In
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Figure 2 Signal transduction in insulin
action. The insulin receptor is a tyrosine
kinase that undergoes
autophosphorylation, and catalyses the
phosphorylation of cellular proteins such
as members of the IRS family, Shc and
Cbl. Upon tyrosine phosphorylation, these
proteins interact with signalling molecules
through their SH2 domains, resulting in a
diverse series of signalling pathways,
including activation of PI(3)K and
downstream PtdIns(3,4,5)P3-dependent
protein kinases, ras and the MAP kinase
cascade, and Cbl/CAP and the activation
of TC10. These pathways act in a
concerted fashion to coordinate the
regulation of vesicle trafficking, protein
synthesis, enzyme activation and
inactivation, and gene expression, which














Figure 1 The regulation of metabolism
by insulin. Insulin is the most potent
anabolic hormone known, and promotes
the synthesis and storage of
carbohydrates, lipids and proteins, while
inhibiting their degradation and release
into the circulation. Insulin stimulates the
uptake of glucose, amino acids and fatty
acids into cells, and increases the
expression or activity of enzymes that
catalyse glycogen, lipid and protein
synthesis, while inhibiting the activity or
expression of those that catalyse
degradation.
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most insulin-responsive cells, Cbl is associated with the adapter 
protein CAP, which binds to proline-rich sequences in Cbl 
through its carboxyl-terminal SH3 domain47. CAP is expressed in
insulin-sensitive tissues, is markedly induced during adipocyte 
differentiation and its expression is increased by insulin-sensitizing
peroxisome proliferator-activated receptor-g (PPARg) agonists48.
CAP belongs to a family of adapter proteins with a common
organization containing three SH3 domains and a region of 
similarity to the peptide sorbin, referred to as a sorbin homology
(SoHo) domain49. Upon phosphorylation, the Cbl–CAP complex
translocates to lipid raft domains in the plasma membrane, mediat-
ed by the interaction of the SoHo domain of CAP with the protein
flotillin50. Expression of dominant-interfering CAP mutants that
cannot bind to Cbl or flotillin inhibit Cbl translocation and insulin-
stimulated glucose uptake. Translocation of phosphorylated Cbl
recruits the adapter protein CrkII to the lipid raft via interaction of
the SH2 domain of CrkII with phospho-Cbl51. CrkII also forms a
constitutive complex with the guanyl nucleotide-exchange protein
C3G. Once translocated into lipid rafts, C3G comes into proximity
with the G protein TC10, and catalyses the exchange of GTP for GDP,
resulting in the activation of the protein51. The localization of 
TC10 in rafts is required for its activation by insulin52. Once 
activated, TC10 seems to provide a second signal to the GLUT4 
protein that functions in parallel with the activation of the PI(3)K
pathway51. This may involve the stabilization of cortical actin, 
which seems to be important in GLUT4 vesicle translocation to the
plasma membrane (see Box 1). 
Insulin-stimulated phosphorylation cascades
As is the case for other growth factors, insulin stimulates the 
mitogen-activated protein (MAP) kinase extracellular signal-
regulated kinase (ERK) (Fig. 2). This pathway involves the tyrosine
phosphorylation of IRS proteins and/or Shc, which in turn interact
with the adapter protein Grb2, recruiting the Son-of-sevenless (SOS)
exchange protein to the plasma membrane for activation of Ras. The
activation of Ras also requires stimulation of the tyrosine 
phosphatase SHP2, through its interaction with receptor substrates
such as Gab-1 or IRS1/2. Once activated, Ras operates as a 
molecular switch, stimulating a serine kinase cascade through 
the stepwise activation of Raf, MEK and ERK. Activated ERK 
can translocate into the nucleus, where it catalyses the phosphoryla-
tion of transcription factors such as p62TCF, initiating a 
transcriptional programme that leads to cellular proliferation or 
differentiation53. Blockade of the pathway with dominant negative
mutants or pharmacological inhibitors prevents the stimulation of
cell growth by insulin, but has no effect on the metabolic actions 
of the hormone54.
Insulin increases synthesis and blocks the degradation of proteins
through activation of mTOR. mTOR is a member of the PI(3)K 
family of proteins, but seems to act primarily as a serine, rather than
lipid kinase55. The stimulation of this protein kinase involves 
PI(3)K activation, although another signal may also be required56.
mTOR can control the mammalian translation machinery by direct
phosphorylation and activation of p70 ribosomal S6 kinase
(p70rsk)57, as well as phosphorylation of the initiation factor 4E 
for eukaryotic translation (eIF-4E) inhibitor, PHAS1 or 4E-binding
protein 1 (ref. 58). P70rsk activates ribosome biosynthesis by 
phosphorylating the ribosomal S6 protein, producing increased
translation of mRNAs with a 58-terminal oligopyrimidine tract.
P70rsk also requires a second PtdIns(3,4,5)P3-dependent phosphory-
lation, presumably catalysed by PDK1. Phosphorylation of PHAS-1
by mTOR results in its dissociation from eIF-2, allowing cap-
dependent translation of mRNAs with a highly structured 
58-untranslated region. Although the mechanism of activation of
mTOR remains unclear, it seems to require the presence of amino
acids in the media for full activation by growth factors, and thus may
also represent a nutrient sensor55.
Glucose and lipid regulation
Regulation of glycogen synthesis
Insulin stimulates glycogen accumulation through a coordinated
increase in glucose transport and glycogen synthesis. The hormone
activates glycogen synthase by promoting its dephosphorylation,
through the inhibition of kinases such as PKA or GSK-3 (ref. 59), and
activation of protein phosphatase 1 (PP1)60. Upon its activation
downstream of PI(3)K, Akt phosphorylates and inactivates 
GSK-3, decreasing the rate of phosphorylation of glycogen 
synthase, thus increasing its activity state59. Insulin does not activate
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Figure 3 The regulation of glucose
metabolism in the liver. In the hepatocyte,
insulin stimulates the utilization and
storage of glucose as lipid and glycogen,
while repressing glucose synthesis and
release. This is accomplished through a
coordinated regulation of enzyme
synthesis and activity. Insulin stimulates
the expression of genes encoding
glycolytic and fatty-acid synthetic
enzymes (in blue), while inhibiting the
expression of those encoding
gluconeogenic enzymes (in red). These
effects are mediated by a series of
transcription factors and co-factors,
including sterol regulatory element-
binding protein (SREBP)-1, hepatic
nuclear factor (HNF)-4, the forkhead
protein family (Fox) and PPARg
co-activator 1 (PGC1). The hormone also
regulates the activities of some enzymes,
such as glycogen synthase and citrate
lyase (in green), through changes in
phosphorylation state. GK, glucokinase; Glucose-6-P, glucose-6-phosphate; 
G-6-Pase, glucose-6-phosphatase; F-1,6-Pase, fructose-1,6-bisphosphatase; 
PEPCK, phosphoenolpyruvate carboxykinase; PFK, phosphofructokinase; PK, pyruvate
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PP1 globally, but rather specifically targets discrete pools of the 
phosphatase, primarily increasing PP1 activity localized at the 
glycogen particle. The compartmentalized activation of PP1 by
insulin is due to glycogen-targeting subunits, which serve as 
‘molecular scaffolds’, bringing together the enzyme directly with 
its substrates glycogen synthase and phosphorylase in a macromolec-
ular complex, and in the process exerting profound effects on PP1 
substrate-specific activity61. 
Four different proteins have been reported to target PP1 to the
glycogen particle. Despite a proposed common function, no two 
targeting subunits share more than 50% sequence homology, and
this is largely confined to the PP1- and glycogen-binding regions.
Overexpression of these scaffolding proteins in cells or in vivo results
in a marked increase in cellular glycogen levels61. Although the 
mechanism by which insulin activates glycogen-associated PP1
remains unknown, inhibitors of PI(3)K block this effect, suggesting
that PtdIns(3,4,5)P3-dependent protein kinases are involved. These
scaffolding proteins have a critical permissive role in the hormonal
activation of the enzyme, perhaps interacting with additional 
proteins that regulate the interaction of PP1 with glycogen synthase
and phosphorylase.
Regulation of gluconeogenesis 
Insulin inhibits the production and release of glucose by the liver by
blocking gluconeogenesis and glycogenolysis (Fig. 3). This occurs
through a direct effect of insulin on the liver62, as well as by indirect
effects of insulin on substrate availability63. Insulin can also influence
glucose metabolism indirectly by changes in free fatty acids generated
from visceral fat, the so called ‘single gateway’ hypothesis64. Because
visceral fat is less sensitive to insulin than subcutaneous fat, even after
a meal there is little suppression of lipolysis by the hormone in this fat
depot. The resulting direct flux of fatty acids derived from these fat
cells through the portal vein to the liver can stimulate glucose 
production, thus providing a signal for both insulin action and
insulin resistance in the liver. 
Insulin directly controls the activities of a set of metabolic
enzymes by phosphorylation or dephosphorylation and also 
regulates the expression of genes encoding hepatic enzymes of 
gluconeogenesis and glycolysis65. It inhibits the transcription of the
gene encoding phosphoenolpyruvate carboxylase, the rate-limiting
step in gluconeogenesis66. The hormone also decreases transcription
of the genes encoding fructose-1,6-bisphosphatase and glucose-6-
phosphatase, and increases transcription of glycolytic enzymes 
such as glucokinase and pyruvate kinase, and lipogenic enzymes 
such as fatty acid synthase and acetyl-CoA carboxylase. Although 
the transcription factors that control the expression of these 
genes have remained elusive, new data suggest a potential role for the 
forkhead family of transcription factors through phosphorylation 
by Akt-related protein kinases39, and the PPARg co-activator 
PGC-1 (ref. 67).
Regulation of lipid synthesis and degradation
As is the case with carbohydrate metabolism, insulin also promotes
the synthesis of lipids, and inhibits their degradation. Recent studies
suggest that many of these changes require an increase in the 
transcription factor steroid regulatory element-binding protein
(SREBP)-1c68. Dominant negative forms of SREBP-1 can block
expression of these gluconeogenic and lipogenic genes69, whereas
overexpression can increase their transcription68. Hepatic SREBP
levels are increased in some rodent models of lipodystrophy, and this
is coordinated with increases in fatty acid synthesis and gluconeoge-
nesis, the exact phenotype observed in genetic models of obesity-
induced diabetes70. Thus, increased expression of SREBP-1c 
might contribute to the insulin resistance observed in liver of 
diabetic rodents, with increased rates of both gluconeogenesis and
lipogenesis. The pathways that account for the changes in SREBP-1c
expression in response to insulin or other metabolic changes are not
known, but probably lie downstream of the IRS/PI(3)K pathway.
In adipocytes, glucose is stored primarily as lipid, owing to
increased uptake of glucose and activation of lipid synthetic
enzymes, including pyruvate dehydrogenase, fatty acid synthase and
acetyl-CoA carboxylase. Insulin also profoundly inhibits lipolysis in
adipocytes, primarily through inhibition of the enzyme hormone-
sensitive lipase71. This enzyme is acutely regulated by control of its
phosphorylation state, which is activated by PKA-dependent 
phosphorylation, and inhibited as a result of a combination of kinase
inhibition and phosphatase activation. Insulin inhibits the activity of
the lipase primarily through reductions in cAMP levels, owing to the
activation of a cAMP-specific phosphodiesterase in fat cells72. 
What causes insulin resistance?
The insulin resistance of obesity and type 2 diabetes is characterized
by defects at many levels, with decreases in receptor concentration
and kinase activity, the concentration and phosphorylation of IRS-1
and -2, PI(3)K activity, glucose transporter translocation, and the
activity of intracellular enzymes10. Activation of the MAP kinase
pathway by insulin is not reduced in type 2 diabetes, perhaps allowing
for some of the detrimental effects of chronic hyperinsulinaemia on
cellular growth in the vasculature73.
Genetic and acquired factors can profoundly influence insulin
sensitivity. Genetic defects in the insulin receptor are relatively rare,
but represent the most severe forms of insulin resistance, and are
exemplified by leprechaunism, the Rabson Mendenhall Syndrome,
and the type A syndrome of insulin resistance74. Differences in 
clinical presentation may be due to the severity of the genetic defect,
the ability of the mutant receptors to form hybrids with IGF-I or
other receptors, and other background genetic or acquired factors
that modify the insulin-resistant state. Type 2 diabetes is polygenic
and may involve polymorphisms in multiple genes encoding the 
proteins involved in insulin signalling, insulin secretion and 
intermediary metabolism75.
Targeted deletions of the components of insulin signalling in vivo
using homologous recombination have yielded some insight into the
complexity of these mechanisms. Although some single defects in the
insulin-signalling pathway, such as knockout of the insulin receptor
IRS-2 or Akt2, can produce diabetes, knockout of the p85 subunit of
PI(3)K, IRS-1 or GLUT4 does not (summarized in Table 1). 
Conversely, knockout of single genes that are involved in turning 
off the insulin signal, such as PTP1B and SHIP2, ameliorate diabetes
in obese rodents23,45. 
Combinatorial knockouts have been produced that mimic 
polygenic type 2 diabetes with heterozygous deletion of the insulin
receptor and IRS-1 (ref. 76), of the insulin receptor, IRS-1 and IRS-2
(ref. 13), and of IRS-1 and glucokinase77. In some of these combina-
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Table 1 Mice phenotypes with single-gene knockouts in signalling pathways
Gene Phenotype Reference
Insulin receptor Normal intrauterine growth; die of diabetic 76
ketoacidosis at 3–7 days
IGF1 receptor Intrauterine and postnatal growth retardation; 97
normal glucose homeostasis
IRS-1 Insulin resistance/impaired glucose tolerance; 11,12
IGF resistance/growth retardation
IRS-2 Insulin resistance/decreased b-cell development; 13,14
type 2 diabetes
IRS-3 Normal growth/normal glucose tolerance 15
IRS-4 Normal growth/normal glucose tolerance 15
Akt2 Insulin resistance in liver and muscle 41
GLUT4 Cardiac hypertrophy/failure; normal glucose 81
tolerance
P85a (hetero) Increased insulin sensitivity; hypoglycaemia 30,31
PTP1B Increased insulin sensitivity; resistance to 23
diet-induced obesity
SHIP2 Increased insulin sensitivity 45
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tions there has been clear evidence of genetic epistasis. For example,
although heterozygous knockout of either the insulin receptor or
IRS-1 alone does not produce diabetes, the double-heterozygous
knockout produces diabetes in up to 50% of mice. This striking 
finding gives insight into human type 2 diabetes, where insulin-
induced downregulation or genetic polymorphisms in the receptor
or IRS-1 alone might produce only modest changes in signalling
capacity, but when combined can lead to diabetes. 
One genetic model that produced a surprising phenotype 
regarding glucose homeostasis emerged from the knockout of the
p85a regulatory subunits of PI(3)K. Although, PI(3)K is central to the
metabolic actions of insulin, p85a heterozygous knockout mice
counter-intuitively exhibit improved insulin sensitivity30,31. Further-
more, superimposition of p85a heterozygosity on the insulin recep-
tor/IRS-1 double-heterozygous knockout protects against diabetes
(Mauvais et al., personal communication). This surprising protection
seems to be due to a unique feature of the insulin-signalling pathway in
which the stoichiometric balance between p85a, the catalytic subunit
p110 and IRS proteins is critical for optimal signal transduction.
The role of specific tissues in the pathogenesis of diabetes has been
explored using the Cre-lox DNA-recombination technology to create
tissue-specific knockouts of the insulin receptor2,62,78,79 and GLUT4
(refs 3,80; see Table 2). Despite the absence of diabetes in mice with a
global knockout of GLUT4 (ref. 81), tissue-specific knockouts of
GLUT4 in muscle80 and fat3 have resulted in severely impaired 
glucose tolerance. Tissue-specific knockout of the insulin receptor
has also produced often surprising results. As noted above, despite
recognition that insulin stimulates glucose uptake primarily in mus-
cle, mice with a knockout of the muscle insulin receptor have normal
glucose tolerance2. This occurs, at least in part, as the result of a shift
of glucose uptake into fat, with subsequent increases in adipose tissue
mass, circulating free fatty acids (FFAs) and triglycerides82. Mice with
a knockout of the fat-specific insulin receptor also have normal glu-
cose tolerance, whereas the liver-specific insulin-receptor knockout
shows both impaired glucose tolerance and decreased insulin clear-
ance with marked hyperinsulinaemia62. Perhaps the most surprising
results, however, have come from studies of mice with knockouts of
the b-cell-specific insulin receptor and neural/brain-specific insulin
receptor79. The former exhibit a marked defect in glucose-stimulated
insulin secretion similar to that observed in type 2 diabetes, whereas
the latter exhibit increased food intake, mild adiposity, insulin resis-
tance and hypertriglyceridaemia, as well as reduced fertility due to
hypothalamic hypogonadism. Taken together, these findings suggest
a unifying hypothesis for type 2 diabetes in which insulin resistance
in classic target tissues, such as liver, muscle and fat, coupled with
insulin resistance in b-cell, brain and other tissues, combine to 
produce the pathophysiology of type 2 diabetes.
The fat cell regulates insulin sensitivity
Free fatty acids
Adipose tissue has a special role in insulin resistance (Fig. 4). 
Circulating FFAs derived from adipocytes are elevated in many
insulin-resistant states and have been suggested to contribute to the
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Table 2 Defects in tissue-specific knockout mice
Gene Tissue Phenotype Reference
Insulin receptor Skeletal Normal glucose tolerance; increased 2,82
muscle fat mass; increased triglycerides 
and FFAs
Liver Impaired glucose tolerance; 62
hyperinsulinaemia and reduced insulin 
clearance; decreased hepatic function
b-cell Loss of glucose-stimulated insulin 5
secretion; progressively impaired 
glucose tolerance; decreased b-cell
growth in adults
Brain Increased appetite; increased fat 79
and leptin; insulin resistance; 
hypothalamic hypogonadism
GLUT4 Skeletal Reduced basal, insulin and 
glucose muscle contraction-stimulated glucose 
transporter transport; severe insulin resistance; 
glucose intolerance 80
Fat Impaired glucose tolerance; 3
hyperinsulinaemia; secondary insulin 
resistance in muscle and liver
Glucokinase b-cell Die within a few days of birth with 98
severe diabetes
Liver Mild hyperglycaemia; pronounced 98
defects in glycogen synthesis and 


























Figure 4 Cross-talk between tissues in
the regulation of glucose metabolism.
Insulin is secreted from the b-cells of the
pancreas in response to elevations in
plasma glucose. The hormone decreases
glucose production from the liver, and
increases glucose uptake, utilization and
storage in fat and muscle. The fat cell is
important in metabolic regulation,
releasing FFAs that reduce glucose uptake
in muscle, insulin secretion from the 
b-cell, and increase glucose production
from the liver. The fat cell can also secrete
‘adipokines’ such as leptin, adiponectin
and TNF, which regulate food intake,
energy expenditure and insulin sensitivity.
© 2001 Macmillan Magazines Ltd
insulin resistance of diabetes and obesity by inhibiting glucose
uptake, glycogen synthesis and glucose oxidation, and by increasing
hepatic glucose output63. Elevated FFAs are also associated with 
a reduction in insulin-stimulated IRS-1 phosphorylation and 
IRS-1-associated PI(3)K activity83. The link between increased 
circulating FFAs and insulin resistance might involve accumulation
of triglycerides and fatty acid-derived metabolites (diacylglycerol,
fatty acyl-CoA and ceramides) in muscle and liver. Nuclear magnetic 
resonance spectroscopy has shown a close correlation between
intramyocellular triglyceride content and whole-body insulin 
resistance in patients with obesity and type 2 diabetes84. Transgenic
mice with muscle- or liver-specific overexpression of lipoprotein
lipase exhibit increases in tissue triglyceride content that correlate
with decreases in insulin action and activation of IRS-associated
PI(3)K85. Activation of PKC and/or IkB kinase and serine 
phosphorylation of the insulin receptor and its substrates might be
important83.
Adipokines
In addition to its role as a storage depot for lipid, the fat cell produces
and secretes a number of hormones, collectively called adipokines,
which may profoundly influence metabolism and energy 
expenditure. Expression of tumour-necrosis factor-a (TNF-a) is
increased in fat of obese rodents and humans, and has been shown to
produce serine phosphorylation of IRS-1, resulting in reduced
insulin receptor kinase activity and insulin resistance19. In rodents,
anti-TNF-a reagents significantly improved insulin resistance86,
although in humans the importance of this mechanism is much
debated, as limited studies of anti-TNF reagents have shown little or
no effect on the insulin-resistant state87.
Leptin is a member of the cytokine family of hormones that is 
produced by adipose tissue and acts on receptors in the central 
nervous system and other sites to inhibit food intake and promote
energy expenditure. Insulin resistance characterizes states of severe
leptin deficiency or resistance, such as ob/ob or db/db mice, or genetic
models of lipoatrophic diabetes. In some of these, administration of
exogenous leptin improves glucose tolerance and insulin sensitivity
independently of effects on food intake, probably by affecting 
neuroendocrine pathways that modulate insulin action in the
liver88,89, although this cytokine might also have direct effects on
hepatic cells90.
Adiponectin (also called Acrp30 or adipoQ) is a fat cell-derived
peptide possessing a collagenous domain at the amino terminus and
a globular domain that shares homology with complement factor
C1q91. Recent studies have shown that expression of adiponectin
mRNA is decreased in obese humans and mice and some models of
lipoatrophic diabetes. Acute treatment of mice with this adipokine
decreases insulin resistance, decreases plasma FFAs and the 
triglyceride content of muscle and liver, and increases expression of
genes involved in fatty-acid oxidation and energy expenditure92. 
In lipoatrophic mice, insulin resistance is reversed by the 
combination of physiological doses of adiponectin and leptin, 
but only partially by either adiponectin or leptin alone. In 
isolated hepatocytes, adiponectin increased the ability of insulin to
suppress glucose production93. A recent genome-wide scan in
humans also mapped a susceptibility locus for type 2 diabetes and
metabolic syndrome to chromosome 3q27 in a region near the
adiponectin gene94.
Resistin is the most recently discovered peptide hormone to be
secreted by adipocytes. Resistin belongs to a family of related secreted
proteins termed RELMs (resistin-like molecules) and FIZZ (found in
inflammatory zone)95. Initial studies suggested that resistin might
cause insulin resistance, as levels were increased in obese mice and
reduced by antidiabetic drugs of the thiazolidinedione class. Further-
more, administration of antiresistin antibody seemed to improve
blood sugar and insulin action in mice with diet-induced obesity. But
subsequent studies have not confirmed these initial findings96. The
potential role of resistin is further complicated by uncertainty about
existence of a human homologue of the hormone.
Perspectives
There has been considerable progress over the past few years in
unravelling the mechanisms of insulin action, and the molecular
defects that give rise to insulin resistance. Recent advances dissecting
the signalling pathways, cellular architecture and spatial compart-
mentalization of proteins, coupled with the sophisticated genetic
analysis of the system, have yielded quantum leaps in our insight into
how proteins and tissues interact to control glucose and lipid 
metabolism. But many gaps remain in our understanding of these
processes, and in the pathophysiology underling insulin resistance.
We need to define the missing steps in the insulin-signalling network,
elucidate the mechanisms of cross-talk in the system, and determine
the genetic susceptibility of insulin resistance and the interactions
between genes and environment. Such studies will provide new
insights into diabetes and insulin resistance, perhaps even allowing a
more focused and individualized approach to therapy or prevention
of these disorders. ■
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